|
Interview
"Our growth might get a boost and it will place us among the 10 leading pharmaceutical companies in the country"
"Perseverance and innovation, inherent parts of the Japanese culture, are powerful weapons in order to be successful in Brazil", stated Alexandre Fernandes, Business Support Director of Takeda in Brazil.
During an exclusive interview to Top Team, the executive, who already worked in Business Development and Strategic Planning, Market Intelligence and SFE at Jansen and at Aché in Market Intelligence, announced that the company will have 15 new launches by 2015.
"The New Business Development area in Brazil is very active and there are many businesses being done likely to be successful. Globally, Takeda invests heavily in R&D, within a vast list of innovative molecules in development (pre-clinic, clinic and phases I, II and III)", highlights the executive.
Check out the main parts of the interview with Alexandre Fernandes:
Is Brazil a strategic country for Takeda?
One of the main reasons that motivated Takeda to acquire Nycomed was its strong presence in the emerging markets, mainly its successful action in Russia and Brazil. Brazil used to be the second biggest Nycomed operation in the world and one with the highest rates of growth. Such important strategic condition has been confirmed right after its acquisition by establishing Brazil not only as a country but mainly as a new "area" in the structure of the organization.
What are the plans of the company for Brazil?
Our plans are to keep on investing and growing. We will keep the high level of investment as we did in 2011 when we created over 130 positions in the sales force. Our growth, which is already one of the major multinational companies in Brazil, should boost and place us as one of the 10 leading pharmaceutical companies in Brazil.
Will there be, therefore, new investments throughout the years?
We have several products to be launched. Such action requires investment from all segments: clinical research, pharmaceutical and technical development, equipment, marketing, sales force, factory, supply chain, quality, medical education and the steady professional development of our contributors.
How many drugs will be launched?
There will be 15 launches by 2015. There other launches about to come, though. The New Business Development area in Brazil is very active and there are many businesses being done likely to be successful. Globally, Takeda invests heavily in R&D, within a vast list of innovative molecules in development (pre-clinic, clinic and phases I, II and III). Dr. Yamada´s nomination for the Chief Medical & Scientific Officer position, recently announced, aims to boost such development and assure that patients may benefit from new treatments as soon as possible.
What is the differential of the company?
First of all the "Takedaism", our philosophy consolidated throughout the 230 years of the company history: Integrity, Equity, Honesty, Perseverance. Secondly, the reliability harnessed with physicians, with the distribution channels, with the authorities and scientific institutions. Solid brands like Dramin, Neosaldina, Pantozol and others assured reliability and the preference of consumers and physicians. Finally, a strong leadership and quick decision taking and implementation allow the company to create competencies in several areas that are a reference in Brazil as well as real competitive differentials.
What are the advantages of being a Japanese company acting in Brazil?
Perseverance and innovation, inherent parts of the Japanese culture, are powerful weapons in order to be successful in Brazil. Credibility and trust in the quality of Japanese products are also very important, mainly when it comes to people´s health.
What are the disadvantages?
Have you ever flown to Tokio? - Laughter - However, due to its importance in Brazil, this distance does not mean being far. Our president often has meetings at the HQ and we receive visitors from the members of the board here in Brazil.
|
Print this page
Mail this page